---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-083183"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:06:32.797195+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics CFO James O'Brien departs; Andrew Einhorn named interim CFO

## Summary
- CFO James O'Brien to leave effective August 12, 2022; departure not due to any disagreement with company or auditors.
- O'Brien eligible for severance: 9 months base salary and health benefits, contingent on release and restrictive covenants.
- Andrew Einhorn appointed Interim CFO effective August 12, via consulting agreement with Danforth Advisors.
- Einhorn previously CFO of RVL Pharmaceuticals and Edge Therapeutics; company will search for permanent CFO.

## SEC filing metadata
- accession: 0001104659-22-083183
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/tm2221873d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-083183
- JSON: https://secwatch.observer/filing/0001104659-22-083183.json
- Plain text: https://secwatch.observer/filing/0001104659-22-083183.txt

## Key facts
- Executive change
  Andrew Einhorn was appointed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm
- Executive change
  James O'Brien departed as Chief Financial Officer at COGNITION THERAPEUTICS INC.
  - Action: departed
  - Role: Chief Financial Officer
  source text: the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.